Amphetamine dependence.
Connell PH.
Proc R Soc Med. 1968 Feb;61(2):178-81. doi: 10.1177/003591576806100228.
Clinical management of psychostimulant withdrawal: review of the evidence.
Li MJ, Shoptaw SJ.
Addiction. 2023 Apr;118(4):750-762. doi: 10.1111/add.16093. Epub 2022 Dec 12.
The applicability of the dependence syndrome to amphetamine.
Topp L, Darke S.
Drug Alcohol Depend. 1997 Nov 25;48(2):113-8. doi: 10.1016/s0376-8716(97)00111-7.
Validation of the amphetamine dependence syndrome and the SAmDQ.
Topp L, Mattick RP.
Addiction. 1997 Feb;92(2):151-62.
Magnesium in drug dependences.
Nechifor M.
Magnes Res. 2008 Mar;21(1):5-15.
Amphetamine-induced movement disorder.
Downes MA, Whyte IM.
Emerg Med Australas. 2005 Jun;17(3):277-80. doi: 10.1111/j.1742-6723.2005.00735.x.
Wide-QRS Complex Tachycardia.
Hanna EB, Johnson CJ, Glancy DL.
Am J Cardiol. 2018 Jan 15;121(2):275-276. doi: 10.1016/j.amjcard.2017.09.035. Epub 2017 Oct 19.
Thymoquinone: From Nigella sativa to a protective pharmacological compound in managing opioid dependence and amphetamine type stimulant issues.
Mohd Adnan LH, Abu Bakar NH, Simbak N, Mohamad N, Ismail R, Ahmad NZ, Mustafa NS, Md Fauzi NFA.
Iran J Basic Med Sci. 2020 Jul;23(7):849-852. doi: 10.22038/ijbms.2020.41678.9841.
Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence.
Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J.
Neuropsychopharmacology. 2008 Jul;33(8):1856-63. doi: 10.1038/sj.npp.1301572. Epub 2007 Oct 24.
Mechanisms and treatments of methamphetamine and HIV-1 co-induced neurotoxicity: a systematic review.
Miao L, Wang H, Li Y, Huang J, Wang C, Teng H, Xu L, Yang X, Tian Y, Yang G, Li J, Zeng X.
Front Immunol. 2024 Aug 19;15:1423263. doi: 10.3389/fimmu.2024.1423263. eCollection 2024.
